<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d325" origId="Lepirudin"><sentence id="DrugDDI.d325.s0" origId="s0" text="Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation"><entity id="DrugDDI.d325.s0.e0" origId="s0.p1" charOffset="27-39" type="drug" text="thrombolytic"/><entity id="DrugDDI.d325.s0.e1" origId="s0.p4" charOffset="46-52" type="drug" text="rt-PA"/><entity id="DrugDDI.d325.s0.e2" origId="s0.p6" charOffset="55-68" type="drug" text="streptokinase"/><entity id="DrugDDI.d325.s0.e3" origId="s0.p16" charOffset="158-166" type="drug" text="REFLUDAN"/><pair id="DrugDDI.d325.s0.p0" e1="DrugDDI.d325.s0.e0" e2="DrugDDI.d325.s0.e1" interaction="false"/><pair id="DrugDDI.d325.s0.p1" e1="DrugDDI.d325.s0.e0" e2="DrugDDI.d325.s0.e2" interaction="false"/><pair id="DrugDDI.d325.s0.p2" e1="DrugDDI.d325.s0.e0" e2="DrugDDI.d325.s0.e3" interaction="false"/><pair id="DrugDDI.d325.s0.p3" e1="DrugDDI.d325.s0.e1" e2="DrugDDI.d325.s0.e2" interaction="false"/><pair id="DrugDDI.d325.s0.p4" e1="DrugDDI.d325.s0.e1" e2="DrugDDI.d325.s0.e3" interaction="false"/><pair id="DrugDDI.d325.s0.p5" e1="DrugDDI.d325.s0.e2" e2="DrugDDI.d325.s0.e3" interaction="false"/></sentence><sentence id="DrugDDI.d325.s1" origId="s1" text="Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding."><entity id="DrugDDI.d325.s1.e0" origId="s1.p19" charOffset="27-35" type="drug" text="coumarin"/><entity id="DrugDDI.d325.s1.e1" origId="s1.p24" charOffset="76-81" type="drug" text="drugs"/><pair id="DrugDDI.d325.s1.p0" e1="DrugDDI.d325.s1.e0" e2="DrugDDI.d325.s1.e1" interaction="true"/></sentence></document>